High-yield map
Key points before the detail
- 01
Use the 1 cm endoscopic threshold plus histological confirmation.
- 02
Document circumferential and maximal extent with Prague C&M.
- 03
Inspect and target visible lesions before random Seattle biopsies.
- 04
Expert pathology confirmation matters before irreversible dysplasia treatment.
- 05
A visible lesion is resected for staging before residual Barrett mucosa is ablated.
1. Definition and cancer context
Barrett's is a marker of increased adenocarcinoma risk, but most people with Barrett's will not develop cancer. Dysplasia can also be overcalled in inflamed mucosa, so diagnostic quality matters as much as the treatment technology.
2. High-quality endoscopy
- Identify the diaphragmatic pinch, top of gastric folds and squamocolumnar junction.
- Measure circumferential (C) and maximal (M) extent using Prague classification.
- Inspect carefully with high-resolution imaging and target any nodule, ulcer or irregularity first.
- After targeted biopsies, use four-quadrant Seattle biopsies every 2 cm for routine surveillance.
3. Current NICE surveillance intervals
| Barrett phenotype | Current surveillance |
|---|---|
| Long segment ≥3 cm | Every 2–3 years. |
| Short segment <3 cm with intestinal metaplasia | Every 3–5 years. |
| Short segment <3 cm without intestinal metaplasia | No surveillance once the diagnosis has been confirmed at two endoscopies. |
4. Management follows histology
| Finding | Management logic |
|---|---|
| No dysplasia | Treat reflux/oesophagitis and continue appropriate surveillance. |
| Indefinite for dysplasia | Optimise acid suppression and repeat expert assessment. |
| Confirmed low-grade dysplasia | Offer RFA after confirmation at two endoscopies and by two GI pathologists. |
| High-grade dysplasia | Resect visible lesions first, then ablate residual Barrett mucosa. |
| T1a adenocarcinoma | Endoscopic resection first-line, followed by ablation of residual Barrett mucosa. |
| High-risk T1b adenocarcinoma | Assess for oesophagectomy if fit. |
5. Why the visible lesion comes first
Endoscopic resection provides invasion depth, margins and lymphovascular information. Ablating first can destroy the specimen needed to decide whether endoscopic treatment is enough.
6. Prevention myths
- Treat reflux symptoms, but do not promise that a PPI eliminates cancer risk.
- Do not offer aspirin solely to prevent Barrett progression.
- Do not offer anti-reflux surgery solely as cancer prevention.
Active recall
Close the notes and answer these
Try each question from memory before revealing the answer. These public prompts are a small preview of the integrated retrieval system inside SurgAtlas.
01How is Barrett's oesophagus defined in this SurgAtlas pathway?
Visible columnar mucosa at least 1 cm above the gastro-oesophageal junction with histological confirmation from oesophageal biopsies.
02What do Prague C and M describe?
Circumferential and maximal extent of Barrett mucosa.
03What is the Seattle biopsy protocol used for?
Systematic four-quadrant biopsies through the Barrett segment after visible lesions have been targeted.
04What is the key rule for a visible dysplastic lesion?
Resect it first for histological staging, then ablate residual Barrett mucosa if appropriate.
05Does high-grade dysplasia automatically mean oesophagectomy?
No. Modern UK management prioritises endoscopic resection of visible disease and eradication of residual Barrett mucosa in appropriate patients.
Sources & editorial basis
References & editorial basis
- SurgAtlas production source. General Surgery — Barrett's Oesophagus. Public lesson curated from the corresponding production chapter.
- NICE NG231. Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management; reviewed May 2026 with surveillance update planned.
This lesson is derived from the corresponding SurgAtlas production teaching material. Where the source makes current management or guideline claims, the public lesson uses the cited contemporary guidance. It is written for education and examination preparation, not as patient-specific clinical advice.
Editorial details
Medical Doctor (MD) · MRCS Part A · Physician · Surgical Educator
SurgAtlas is an educational resource. For patient care, verify current national guidance, local antimicrobial and transfusion policies, specialty pathways and individual patient factors.
Continue in SurgAtlas
Turn reading into retrieval.
Use the full learning workspace for chapter progress, integrated questions, review scheduling and exam-focused study tools. Free accounts do not include recurring AI usage.